[1]黄伟,潘起航,马钊,等.脑膜中动脉栓塞治疗慢性硬膜下血肿的疗效[J].中国临床神经外科杂志,2024,29(08):462-464.[doi:10.13798/j.issn.1009-153X.2024.08.004]
　HUANG Wei,PAN Qi-hang,MA Zhao,et al.Efficacy of embolization of the middle meningeal artery for patients with chronic subdural hematomas[J].,2024,29(08):462-464.[doi:10.13798/j.issn.1009-153X.2024.08.004]
点击复制

脑膜中动脉栓塞治疗慢性硬膜下血肿的疗效()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年08期
页码:
462-464
栏目:
论著
出版日期:
2024-08-30

文章信息/Info

Title:
Efficacy of embolization of the middle meningeal artery for patients with chronic subdural hematomas
文章编号:
1009-153X（2024）08-0462-03
作者:
黄伟; 潘起航; 马钊; 李俊; 陈文
430014武汉，华中科技大学同济医学院附属武汉中心医院神经外科（黄伟、潘起航、马钊、李俊、陈文）
Author(s):
HUANG Wei;  PAN Qi-hang;  MA Zhao;  LI Jun;  CHEN Wen
Department of Neurosurgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
关键词:
慢性硬膜下血肿; 脑膜中动脉栓塞; 疗效
Keywords:
Chronic subdural hematomas;  Middle meningeal artery embolization;  Clinical efficacy
分类号:
R 651.1+5; R 815.2
DOI:
10.13798/j.issn.1009-153X.2024.08.004
文献标志码:
A
摘要:
目的 探讨脑膜中动脉栓塞（MMAE）治疗慢性硬膜下血肿（CSDH）的临床疗效。方法 回顾性分析2020年1月至2022年1月行MMAE治疗的12例CSDH的临床资料。结果 3例为双侧血肿，9例为单侧。12例病人共进行15侧MMAE，其中9侧行单纯栓塞治疗，6侧行钻孔引流术后辅助栓塞治疗；栓塞剂为微球颗粒9侧，Onyx胶5侧，弹簧圈结合颗粒1侧。术后1例出现单眼永久性失明，2例出现下颌神经区域疼痛。术后3~6个月随访，所有病人血肿体积明显减少或吸收，未见血肿复发。结论 MMAE是防治CSDH进展和复发的有效方法，但早期开展需仔细辨认脑膜血管变异与吻合，防止严重并发症。
Abstract:
Objective To explore the clinical efficacy of middle meningeal artery embolization (MMAE) in the treatment of chronic subdural hematomas (CSDH). Methods The clinical data of 12 patients with CSDH treated with MMAE from January 2020 to January 2022 were retrospectively analyzed. Results Three cases had bilateral hematomas, and nine cases had unilateral ones. A total of 15 MMAEs were performed in 12 patients, among which 9 were treated with embolization alone and 6 were treated with adjunctive embolization after burr hole drainage. The embolic agents included microsphere particles in 9 cases, Onyx glue in 5 cases, and coils combined with particles in 1 case. After the operation, one case had permanent monocular blindness, and two cases had pain in the mandibular nerve region. During the 3~6 months of follow-up after the operation, the hematoma volume of all patients was significantly reduced or absorbed, and no recurrence of hematoma was observed. Conclusion MMAE is an effective method for preventing the progression and recurrence of CSDH. However, in the early stage of implementation, careful identification of meningeal vascular variations and anastomoses is necessary to prevent serious complications.

参考文献/References:

[1]EDLMANN E, HOLL DC, LINGSMA HF, et al. Systematic review of current randomised control trials in chronic subdural haematoma and proposal for an international collaborative approach[J]. Acta Neurochir (Wien), 2020, 162(4): 763-776.
[2]NAKAGUCHI H, TANISHIMA T, YOSHIMASU N. Factors in the natural history of chronic subdural hematomas that influence their postoperative recurrence[J]. J Neurosurg, 2001, 95(2): 256-262.
[3]EDLMANN E, GIORGI-COLL S, WHITFIELD PC, et al. Pathophy-siology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy[J]. J Neuroinflammation, 2017, 14(1): 108.
[4]LINK TW, RAPOPORT BI, PAINE SM, et al. Middle meningeal artery embolization for chronic subdural hematoma: endovascular technique and radiographic findings[J]. Interv Neuroradiol, 2018, 24(4): 455-462.
[5]MANDAI S, SAKURAI M, MATSUMOTO Y. Middle meningeal artery embolization for refractory chronic subdural hematoma[J]. J Neurosurg, 2000, 93(4): 686-688.
[6]LINK TW, BODDU S, PAINE SM, et al. Middle meningeal artery embolization for chronic subdural hematoma: a series of 60 cases [J]. Neurosurgery, 2019, 85(6): 801-807.
[7]KAN P, MARAGKOS GA, SRIVATSAN A, et al. Middle meningeal artery embolization for chronic subdural hematoma: a multi-center experience of 154 consecutive embolizations[J]. Neurosurgery, 2021, 88(2): 268-277.
[8]IRONSIDE N, NGUYEN C, DO Q, et al. Middle meningeal artery embolization for chronic subdural hematoma: a systematic review and meta-analysis[J]. J Neurointerv Surg, 2021, 13(10): 951-957.

相似文献/References:

[1]庞陆军　张恒柱　李育平　严正村　王杏东　魏　民.慢性硬膜下血肿术前影像学分型和手术治疗[J].中国临床神经外科杂志,2016,(02):101.[doi:10.13798/j.issn.1009-153X.2016.02.014]
[2]王林风　郑华山　操　廉　李庆阳　贾俊峰　丁　磊　张　武.钻孔引流术治疗慢性硬膜下血肿90例[J].中国临床神经外科杂志,2016,(02):109.[doi:10.13798/j.issn.1009-153X.2016.02.018]
[3]王　斌　杨秀莹.高位颅骨钻孔引流术治疗慢性硬膜下血肿[J].中国临床神经外科杂志,2016,(02):115.[doi:10.13798/j.issn.1009-153X.2016.02.021]
[4]孙成法　姜　华　褚荣涛　金　科.671例慢性硬膜下血肿的临床分析[J].中国临床神经外科杂志,2016,(01):42.[doi:10.13798/j.issn.1009-153X.2016.01.015]
[5]陈　新　张传玲　王伟功.锥颅引流术与钻孔冲洗引流术治疗慢性硬膜下血肿的疗效对比分析[J].中国临床神经外科杂志,2016,(01):53.[doi:10.13798/j.issn.1009-153X.2016.01.020]
[6]黄海源　颜庆华　张　猛　丁兴进　刘　枫　沈建华　史　俊.慢性硬膜下血肿钻孔引流术中持续冲洗的临床效果[J].中国临床神经外科杂志,2016,(01):55.[doi:10.13798/j.issn.1009-153X.2016.01.021]
[7]曾昭戎.慢性硬膜下血肿钻孔引流术中尿激酶的应用体会[J].中国临床神经外科杂志,2015,(08):491.[doi:10.13798/j.issn.1009-153X.2015.08.017]
[8]李乾锋　吴京雷　杨国平.神经内镜手术治疗慢性硬膜下血肿50例[J].中国临床神经外科杂志,2015,(09):557.[doi:10.13798/j.issn.1009-153X.2015.09.017]
[9]江敦清　宋熙文　陈世文.IL-6和VEGF在慢性硬膜下血肿中的检测及意义[J].中国临床神经外科杂志,2015,(05):287.[doi:10.13798/j.issn.1009-153X.2015.05.010]
　JIANG Dun-qing,SONG Xi-wen,CHEN Shi-wen..Detection of IL-6 and VEGF levels in chronic subdural hematomas and their meanings[J].,2015,(08):287.[doi:10.13798/j.issn.1009-153X.2015.05.010]
[10]盖延廷　贺子建.钻孔引流术与钻孔冲洗术治疗慢性硬膜下血肿疗效的Meta分析[J].中国临床神经外科杂志,2015,(05):293.[doi:10.13798/j.issn.1009-153X.2015.05.012]
[11]钱尧轩,庄敏杰,周志杰,等.硬通道穿刺引流术联合脑膜中动脉栓塞治疗合并高危复发因素的慢性硬膜下血肿[J].中国临床神经外科杂志,2024,29(11):655.[doi:10.13798/j.issn.1009-153X.2024.11.004]
　QIAN Yao-xuan,ZHUANG Min-jie,ZHOU Zhi-jie,et al.Safety and effectiveness of hard channel puncture and drainage combined with middle meningeal artery embolization for chronic subdural hema-tomas with high-risk recurrence factors[J].,2024,29(08):655.[doi:10.13798/j.issn.1009-153X.2024.11.004]

备注/Memo

备注/Memo:
（2023-02-22收稿，2024-06-11修回）
通信作者：陈　文，Email：853329529@163.com
更新日期/Last Update: 2024-08-30